🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

46+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 46 recruiting trials for “moderate-hemophilia-b”

Phase 4RecruitingNCT05936580 ↗

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

👨‍⚕️ Johannes Oldenburg, Experimental Haematology and Transfusion Medicine, University Clinic Bonn📍 15 sites📅 Started Apr 2026View details ↗
Phase 4RecruitingNCT07406139 ↗

PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）

🏥 Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Mar 2026View details ↗
Phase 3RecruitingNCT04563520 ↗

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

👨‍⚕️ Robert Sidonio, MD, Emory University📍 2 sites📅 Started Mar 2026View details ↗
RecruitingNCT07101926 ↗

Monitoring of Anti-TFPI in Hemophilia

🏥 Hospices Civils de Lyon📍 2 sites📅 Started Oct 2025View details ↗
Phase 4RecruitingNCT06941870 ↗

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

🏥 Sanofi📍 13 sites📅 Started Sep 2025View details ↗
RecruitingNCT07314983 ↗

Long-term Anticoagulation in a Patient With Severe Hemophilia A

🏥 University Hospital, Strasbourg, France📍 1 site📅 Started Sep 2025View details ↗
Phase 4RecruitingNCT06940830 ↗

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

👨‍⚕️ Study Physician, Swedish Orphan Biovitrum AB (publ)📍 27 sites📅 Started May 2025View details ↗
Phase 1RecruitingNCT06703606 ↗

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

👨‍⚕️ Pfizer CT.gov Call Center, Pfizer📍 4 sites📅 Started May 2025View details ↗
Phase 3RecruitingNCT06833983 ↗

To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

🏥 Gritgen Therapeutics Co., Ltd.📍 13 sites📅 Started Mar 2025View details ↗
Phase 4RecruitingNCT06864975 ↗

Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)

🏥 Runhui WU📍 1 site📅 Started Mar 2025View details ↗
Phase 1RecruitingNCT06579144 ↗

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

👨‍⚕️ Elena Santagostino, MD, Sobi AB📍 8 sites📅 Started Feb 2025View details ↗
NARecruitingNCT06816056 ↗

Manual Therapy in Hemophilic Arthropathy of the Ankle

👨‍⚕️ Rubén Cuesta-Barriuso, PhD, Universidad de Oviedo📍 1 site📅 Started Feb 2025View details ↗
Phase 3RecruitingNCT06738485 ↗

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

👨‍⚕️ Study Director, CSL Behring📍 20 sites📅 Started Jan 2025View details ↗
RecruitingNCT06684314 ↗

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan

🏥 Sanofi📍 10 sites📅 Started Nov 2024View details ↗
Phase 3RecruitingNCT06700096 ↗

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

👨‍⚕️ Arina Arina V Zinkina-Orikhan, Biocad📍 14 sites📅 Started Nov 2024View details ↗
NARecruitingNCT06565481 ↗

Measurement Properties in People with Hemophilia

👨‍⚕️ Ruud Knols, PhD, University of Zurich📍 1 site📅 Started Oct 2024View details ↗
Enrolling by InvitationNCT06826209 ↗

Comparison of Upper Extremity Functional Performance in Hemophilic and Healthy Children

🏥 Hacettepe University📍 1 site📅 Started Oct 2024View details ↗
Phase 1, PHASE2RecruitingNCT06379789 ↗

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

👨‍⚕️ Clinical Trial Management, Regeneron Pharmaceuticals📍 40 sites📅 Started Sep 2024View details ↗
NARecruitingNCT06580340 ↗

Effectiveness of an Adapted Physical Activity Program for Subjects Suffering From Haemophilia

🏥 Istituto Ortopedico Rizzoli📍 1 site📅 Started Sep 2024View details ↗
NAEnrolling by InvitationNCT07259356 ↗

Feasibility and Safety of Blood-Flow-Restriction Training in Patients With Hemophilia

🏥 University Hospital, Bonn📍 1 site📅 Started Aug 2024View details ↗
Page 1 of 3Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →